Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis (NCT06899399) | Clinical Trial Compass
RecruitingNot Applicable
Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis
China982 participantsStarted 2024-10-18
Plain-language summary
This study is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the safety and efficacy of endovascular stenting combined with optimal medical therapy versus optimal medical therapy alone in patients with asymptomatic severe stenosis (70-99%) of the internal carotid artery. The study plans to enroll 982 patients aged 40-80 years who have had no ipsilateral carotid artery-related neurological symptoms in the past six months and who have declined carotid endarterectomy. The primary endpoints include stroke, myocardial infarction, or death within 30 days post-procedure/enrollment, as well as the incidence of ipsilateral stroke from 30 days to one year post-procedure/enrollment. Secondary endpoints include procedural success rate, restenosis rate, changes in cognitive function, and others. The study results will provide high-level evidence-based medical evidence for the treatment selection of patients with asymptomatic carotid artery stenosis.
Who can participate
Age range40 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 40-80 years
✓. Severe asymptomatic internal carotid artery stenosis (70-99%) confirmed by ultrasound/CTA/DSA
✓. Contralateral ICA stenosis \<70%
✓. No TIA/stroke related to target lesion in past 6 months
✓. Declined carotid endarterectomy
✓. Willing to complete 12-month follow-up
✓. Signed informed consent by participant/legal representative
Exclusion criteria
✕. symptomatic internal carotid artery stenosis in the past 6 months
✕. Spontaneous intracranial hemorrhage in nearly one year
✕. Patients with larger intracranial aneurysms (diameter \>5 mm) who cannot undergo prior or concurrent treatment
✕
What they're measuring
1
Efficacy endpoint
Timeframe: Within 30 days/ between 30 days and 12 months post-enrollment or post-procedure